期刊文献+

放射线照射后NK-92细胞对人宫颈癌细胞体外杀伤活性的研究 被引量:2

In Vitro Cytotoxic Activity of Irradiated NK-92 Cells against Human Cervical Cancer Cells
下载PDF
导出
摘要 目的研究放射线照射后NK-92细胞对人宫颈癌细胞的体外杀伤活性.方法应用医用电子直线加速器对NK-92细胞进行照射处理(0、400cGy)后,以体外培养人宫颈癌细胞系Hela为靶细胞,以NK-92的敏感细胞株K562作为对照,应用4h51Cr释放法检测不同效靶比情况下NK-92细胞的杀伤活性.结果 NK-92细胞0 cGy照射组,效靶比较低时(1∶1 、5∶1) 对Hela细胞杀伤率为15%~33% ,随效靶比升高,杀伤率随之上升,10∶1 时杀伤率显著上升为47%, 20∶1时杀伤率仅上升了3%;对于K562细胞,杀伤率为33%~69%.400cGy 组照射后2d , NK-92细胞对Hela细胞不同效靶比的杀伤率与0cGy 组相比稍有降低,其总体杀伤率为14%~47%,对K562 细胞杀伤范围在30%~60%之间.结论放射线照射后的NK-92 细胞对人宫颈癌Hela细胞系具有一定的杀伤活性. Objective To study in vitro cytotoxic activity of NK-92 cells against human cervical cancer cells and effect of irradiation on NK-92 cytotoxicity.Methods NK-92 cells were mixed with 51 Cr-labeled Hela or K562 cells at different effector-to-target ratios for a 4h 51 Cr-release assay. On the other hand, NK-92 cells were irradiated at 0 and 400 cGy and tested after 2d for cytotoxicity against K562 and Hela cells.Results NK-92 cells (0 cGy) displayed high in vitro cytotoxicity against Hela with a mean specific lysis of 47% and 50% at 10∶1 and 20∶1 E∶T ratios , while these levels at 1∶1 (15 %) and 5∶1 (33 %) E∶T ratios were lower; The cytotoxicity of NK-92 against K562 ranged from 33 % to 69 %. NK–92 cells maintained up to 14 %~47 % cytotoxicity against Hela and 30%~60% cytotoxicity against K562 when irradiated with 400cGy after 2d.Conclusion In vitro cytotoxic activity of NK-92 cells against Hela cells is high at suitable E∶T ratios,and substantial cytotoxicity can be retained up to irradiation dose of 400cGy.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2005年第6期357-359,共3页 Cancer Research on Prevention and Treatment
基金 国家863计划资助课题(2002AA216151)
关键词 杀伤细胞 天然/免疫学 肿瘤细胞 培养 Killer cells Natural/ immunology Tumor cells Culture
  • 相关文献

参考文献11

  • 1Gong J H ,Maki G,Klingemann HG.Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells[J].Leukemia,1994,8 (4) : 652-658.
  • 2Yan Y,Steinherz P ,Klingemann HG,et al .Antileukemia activity of a natural killer cell line against human leukemia[J].Clin Cancer Res ,1998,4 (11) : 2859-2868.
  • 3Tam YK,Miyagawa B,Ho VC,et al .Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92[J].J Hematother ,1999,8 (3) :281-290.
  • 4Tam YK,Miyagawa B,Ho VC,et al.Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92[J].J Hematother ,1999,8(3):281-290.
  • 5陈纲,凌斌,祝怀平,赵卫东,张红雁,吴爱东,魏海明,田志刚.NK-92细胞对人卵巢癌细胞体外杀伤活性[J].安徽医科大学学报,2004,39(2):90-93. 被引量:2
  • 6凌斌,陈纲,祝怀平,赵卫东,王群华,张红雁,吴爱东,魏海明,田志刚.照射后NK-92细胞对人卵巢癌细胞杀伤活性的研究[J].现代妇产科进展,2004,13(4):251-254. 被引量:5
  • 7Tam YK,Maki G,Miyagawa B,et al .Characterization of genetically altered,interleukin-2 independent natural killer cell lines suitable for adoptive cellular immunotherapy[J].Hum Gene Ther,1999,10 (8) :1359-1373.
  • 8凌斌,王波.子宫颈癌患者预后相关因素研究进展[J].国外医学(妇产科学分册),1997,24(5):281-283. 被引量:1
  • 9Basse P,Herberman RB,Nannmark U,et al .Accumulation of adoptively transferred adherent,lymphokine-activated killer cells in murine metastases[J].J Exp Med ,1991,174 (2) : 479-488.
  • 10Rosenberg SA,Lotze MT,Yang JC,et al.Prospective randomized trial of highdose interleukin-2 alone or in conjunction with lymphokine2activated killer cells for the treatment of patients with advanced cancer[J].J Natl Cancer Inst ,1993,85 (8) : 622-632.

二级参考文献21

  • 1Yan Y,Steinherz P,Klingemann HG,et al.Antileukemia activity of a natural killer cell line against human leukemia[J].Clin Cancer Res,1998,4:2859-2868
  • 2Klingemann HG,Wong E,Maki G.A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood[J]. Biol Blood Marrow Transplant,1996,2:68-75
  • 3Tam YK,Maki G,Miyagawa B,et al.Characterization of genetically altered,interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy[J].Hum Gene Ther,1999,10:1359-1373
  • 4Tam YK,Miyagawa B,Ho VC,et al.Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92[J].J Hematother,1999,8:281-290
  • 5Ochsenbein AF,Sierro S,Odermatt B,et al.Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction[J].Nature,2001,411:1058-1064
  • 6Basse P,Herberman RB,Nannmark U,et al.Accumulation of adoptively transferred adherent,lymphokine-activated killer cells in murine metastases[J].J Exp Med,1991,174:479-488
  • 7Crowley NJ,Vervaert CE,Seigler HF.Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T cells[J].Cancer Res,1992,52:394-399
  • 8Rosenberg SA,Lotze MT,Yang JC,et al.Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer[J].J Natl Cancer Inst,1993,85:622-632
  • 9Rosenberg SA,Yannelli JR,Yang JC,et al.Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2[J].J Natl Cancer Inst,1994,86:1159-1166
  • 10Rosenberg SA,Muul LM,Leitman S,et al.Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer[J].N Engl J Med,1985,313:1485-1492

共引文献5

同被引文献21

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部